Proactive Investors - Run By Investors For Investors

Zelda shareholders granted priority on float of CannPal Animal Therapeutics

CannPal is a pet pharmaceutical company and has lodged a prospectus with ASIC.
Zelda shareholders granted priority on float of CannPal Animal Therapeutics
CannPal is a pet pharmaceutical company

Zelda Therapeutics Ltd (ASX:ZLD) has a strategic collaborative partnership with CannPal Animal Therapeutics, which is in the process of listing on the ASX.

The companies are looking to exploit opportunities of mutual interest in both the human and animal pharmaceutical markets through the sharing of research data compiled by each of the parties.

CannPal is looking to strengthen the ties between the companies by inviting Zelda shareholders to participate as a priority applicant in the prospectus capital raising lodged with ASIC.

The prospectus is to raise $6 million.

Prospectus and offer details

Under the prospectus, 5 million shares at $0.20 have been allocated and made available to Zelda shareholders registered on the 1st September 2017 holding a minimum of 25,000 shares.

The minimum subscription in CannPal is 10,000 shares worth $2,000.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

cannabis plant
March 09 2019
The Vancouver company's recent move into Jamaica, which covers the acquisition of 145 acres of cultivation property, will pave the way for the development of cannabis brands for the island nation
cannabis tablet
March 01 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
A WeedMD greenhouse
January 22 2019
WeedMD produces cannabis and cannabis oil for both the medical and adult-use markets

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use